Rezultati pretrage - Jeffrey Matous

Detaljiziraj rezultate
  1. 1
    A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

    A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma od James R. Berenson, Jeffrey Matous, Regina A. Swift, Russell Mapes, Blake Morrison, Howard Yeh

    Izdano 2007
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  2. 2
    Combination trial of duvelisib (IPI‐145) with rituximab or bendamustine/rituximab in patients with non‐Hodgkin lymphoma or chronic lymphocytic leukemia

    Combination trial of duvelisib (IPI‐145) with rituximab or bendamustine/rituximab in patients with non‐Hodgkin lymphoma or chronic lymphocytic leukemia od Ian W. Flinn, Mohamad Cherry, Michael B. Maris, Jeffrey Matous, Jesús G. Berdeja, Manish R. Patel

    Izdano 2019
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  3. 3
    Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment

    Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment od Baiteng Zhao, Robert Chen, Owen A. O’Connor, Ajay K. Gopal, Radhakrishnan Ramchandren, André Goy, Jeffrey Matous, Adedigbo A. Fasanmade, Thomas Manley, Tae Hyung Han

    Izdano 2016
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  4. 4
    CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody−Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies

    CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody−Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies od Tae Hyung Han, Ajay K. Gopal, Radhakrishnan Ramchandren, André Goy, Robert Chen, Jeffrey Matous, Maureen Cooper, Laurie E. Grove, Stephen C. Alley, Carmel M. Lynch, Owen A. O’Connor

    Izdano 2013
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  5. 5
    Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma

    Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma od Sham Mailankody, Jeffrey Matous, Michaela Liedtke, Surbhi Sidana, Shahbaz A. Malik, Rajneesh Nath, Olalekan O. Oluwole, Erin E. Karski, Wade Lovelace, Xiangdong Zhou, Srinand Ponnathapura Nandakumar, Arun Balakumaran, Parameswaran Hari

    Izdano 2020
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  6. 6
    Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

    Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation od Ajay K. Gopal, Radhakrishnan Ramchandren, Owen A. O’Connor, R.B. Berryman, Ranjana H. Advani, Robert Chen, Scott E. Smith, Maureen Cooper, Achim Rothe, Jeffrey Matous, Laurie E. Grove, Jasmine Zain

    Izdano 2012
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  7. 7
    Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G-CSF and Plerixafor Compared to G-CSF and Cyclophosphamide

    Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G-CSF and Plerixafor Compared to G-CSF and Cyclophosphamide od Paul Shaughnessy, Miguel Islas‐Ohlmayer, Julie A. Murphy, Maureen Hougham, Jill MacPherson, Kurt Winkler, Matthew J. Silva, Michael Steinberg, Jeffrey Matous, Sheryl Selvey, Michael B. Maris, Peter A. McSweeney

    Izdano 2010
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  8. 8
    Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia

    Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia od Steven P. Treon, Andrew R. Branagan, Leukothea Ioakimidis, Jacob D. Soumerai, Christopher J. Patterson, Barry Turnbull, Parveen Wasi, Christos Emmanouilides, Stanley R. Frankel, Andrew Lister, Pierre Morel, Jeffrey Matous, Stephanie A. Gregory, Eva Kimby

    Izdano 2008
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  9. 9
    S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY

    S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY od Fritz Offner, O. Decaux, Cyrille Hulin, Sébastien Anguille, Anne Sophie Michallet, Luciano J. Costa, Cyrille Touzeau, Kevin Boyd, Deeksha Vishwamitra, Yue Guo, Zhuolu Niu, Julie S. Larsen, Lingling Chen, Arnob Banerjee, Jenna D. Goldberg, Jeffrey Matous

    Izdano 2023
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  10. 10
    Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

    Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study od Barbara Pro, Ranjana H. Advani, Pauline Brice, Nancy L. Bartlett, Joseph D. Rosenblatt, Tim Illidge, Jeffrey Matous, Radhakrishnan Ramchandren, Michelle A. Fanale, Joseph M. Connors, Yin Yang, Eric L. Sievers, Dana A. Kennedy, Andrei R. Shustov

    Izdano 2012
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  11. 11
    Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

    Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies od Nancy L. Bartlett, Robert Chen, Michelle A. Fanale, Pauline Brice, Ajay K. Gopal, Scott E. Smith, Ranjana H. Advani, Jeffrey Matous, Radhakrishnan Ramchandren, Joseph D. Rosenblatt, Dirk Huebner, Pamela Levine, Laurie E. Grove, Andres Forero‐Torres

    Izdano 2014
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  12. 12
    Talquetamab + Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study

    Talquetamab + Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Preliminary Efficacy Results from the Phase 1b MonumenTAL-2 Study od Jeffrey Matous, Noa Biran, Aurore Perrot, Jesús G. Berdeja, Kathleen A. Dorritie, Janine van Elssen, Emma Searle, Cyrille Touzeau, Sébastien Anguille, Deeksha Vishwamitra, Ashley Nguyen, Debopriya Ghosh, Elizabeth Shearin, Katherine A. Thornton, Damiette Smit, Hang Quach

    Izdano 2023
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  13. 13
    Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia

    Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia od Irene M. Ghobrial, Fangxin Hong, Swaminathan P. Iyer, Ashraf Badros, Meghan Rourke, Renee Leduc, Stacey Chuma, Janet Kunsman, Diane Warren, Brianna Harris, Amy Sam, Kenneth C. Anderson, Paul G. Richardson, Steven P. Treon, Edie Weller, Jeffrey Matous

    Izdano 2010
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  14. 14
    Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study

    Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study od Nathan Fowler, Brad S. Kahl, Peter P. Lee, Jeffrey Matous, Amanda F. Cashen, Samuel A. Jacobs, Jeffrey Letzer, Bipinkumar Amin, Michael E. Williams, Sonali M. Smith, Alfred Saleh, Peter J. Rosen, Hongliang Shi, Sudha Parasuraman, Bruce D. Cheson

    Izdano 2011
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  15. 15
    Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma

    Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma od Barbara Pro, Ranjana H. Advani, Pauline Brice, Nancy L. Bartlett, Joseph D. Rosenblatt, Tim Illidge, Jeffrey Matous, Radhakrishnan Ramchandren, Michelle A. Fanale, Joseph M. Connors, Keenan Fenton, Dirk Huebner, Juan Pinelli, Dana A. Kennedy, Andrei R. Shustov

    Izdano 2017
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  16. 16
    Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia

    Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia od Irene M. Ghobrial, Federico Campigotto, Timothy J. Murphy, Erica N Boswell, Ranjit Banwait, Feda Azab, Stacey Chuma, Janet Kunsman, Amanda Donovan, Farzana Masood, Diane Warren, Scott J. Rodig, Kenneth C. Anderson, Paul G. Richardson, Edie Weller, Jeffrey Matous

    Izdano 2013
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  17. 17
    Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared With Allopurinol Alone—Results of a Multicenter Phase III Study

    Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared With Allopurinol A... od Jorge E. Cortés, Joseph O. Moore, Richard T. Maziarz, Meir Wetzler, Michael Craig, Jeffrey Matous, Selina M. Luger, Bimalangshu R. Dey, Gary J. Schiller, Dat C. Pham, Camille N. Abboud, Muthuswamy Krishnamurthy, Archie W. Brown, Abderrahmane Laadem, Karen Seiter

    Izdano 2010
    Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  18. 18
    Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia

    Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia od Irene M. Ghobrial, Wanling Xie, Swaminathan P. Iyer, Ashraf Badros, Meghan Rourke, Renee Leduc, Stacey Chuma, Janet Kunsman, Diane Warren, Tiffany Poon, Brianna Harris, Amy Sam, Kenneth C. Anderson, Paul G. Richardson, Steven P. Treon, Edie Weller, Jeffrey Matous

    Izdano 2010
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  19. 19
    Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

    Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma od Christine Chen, Donna Reece, David S. Siegel, Rubén Niesvizky, Ralph V. Boccia, Edward A. Stadtmauer, Rafat Abonour, Paul G. Richardson, Jeffrey Matous, Shaji Kumar, Nizar J. Bahlis, Melissa Alsina, Robert Vescio, Steven Coutré, Dennis Pietronigro, Robert Knight, Jerome B. Zeldis, S. Vincent Rajkumar

    Izdano 2009
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:
  20. 20
    Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180

    Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180 od Steven P. Treon, Leukothea Ioakimidis, Jacob D. Soumerai, Christopher J. Patterson, Patricia Sheehy, Marybeth Nelson, Michael A. Willen, Jeffrey Matous, John Q. A. Mattern, Jakow G. Diener, George P. Keogh, Thomas J. Myers, Andy Boral, Ann Birner, Dixie Esseltine, Irene M. Ghobrial

    Izdano 2009
    Preuzmi cijeli tekst Preuzmi cijeli tekst
    Artigo
    Spremi u popis
    Spremljeno u:

Alati za pretragu: